- Home
- FMX vs GILD Comparison
FMX vs GILD Comparison
Compare FMX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMX
- GILD
- Stock Information
- Founded
- FMX 1890
- GILD 1987
- Country
- FMX Mexico
- GILD United States
- Employees
- FMX N/A
- GILD N/A
- Industry
- FMX Beverages (Production/Distribution)
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMX Consumer Staples
- GILD Health Care
- Exchange
- FMX Nasdaq
- GILD Nasdaq
- Market Cap
- FMX 148.0B
- GILD 144.1B
- IPO Year
- FMX 1998
- GILD 1992
- Fundamental
- Price
- FMX $94.37
- GILD $112.54
- Analyst Decision
- FMX Buy
- GILD Buy
- Analyst Count
- FMX 7
- GILD 23
- Target Price
- FMX $101.63
- GILD $115.68
- AVG Volume (30 Days)
- FMX 948.9K
- GILD 5.9M
- Earning Date
- FMX 10-27-2025
- GILD 11-05-2025
- Dividend Yield
- FMX 5.38%
- GILD 2.81%
- EPS Growth
- FMX N/A
- GILD 496.80
- EPS
- FMX 0.30
- GILD 5.01
- Revenue
- FMX $43,105,359,505.00
- GILD $28,863,000,000.00
- Revenue This Year
- FMX $12.60
- GILD $2.01
- Revenue Next Year
- FMX $8.78
- GILD $4.03
- P/E Ratio
- FMX $28.33
- GILD $22.46
- Revenue Growth
- FMX 9.84
- GILD 3.81
- 52 Week Low
- FMX $81.08
- GILD $81.83
- 52 Week High
- FMX $108.74
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- FMX 66.74
- GILD 43.82
- Support Level
- FMX $84.67
- GILD $112.25
- Resistance Level
- FMX $87.89
- GILD $118.11
- Average True Range (ATR)
- FMX 2.11
- GILD 2.04
- MACD
- FMX 1.21
- GILD -0.15
- Stochastic Oscillator
- FMX 97.79
- GILD 18.45
About FMX Fomento Economico Mexicano S.A.B. de C.V.
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up 75% of total company revenue and over 90% of profits in 2024.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).